[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558341":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":50,"collaborators":54,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":30,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":30,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":93,"whyStopped":30,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PD-1 Inhibitor Combined With Progesterone Treatment","EXPERIMENTAL","All participants",[13],"Drug: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)\u002F megestrol acetate (MA)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)\u002F megestrol acetate (MA)","1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks\n2. MA, 320mg\u002FMPA, 500mg, po, once a day",[9],[21],"Sintilimab or Pembrolizumab and MPA\u002FMA",[23],{"name":24,"affiliation":5,"role":25},"Jianliu Wang, Professor","STUDY_CHAIR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","0086-010-88324381",null,"wangjianliu1203@163.com",{"name":33,"role":28,"phone":30,"phoneExt":30,"email":34},"Yiqin Wang","emily_wang92@163.com",[36],{"facility":5,"status":30,"city":37,"state":38,"zip":30,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Beijing","Beijing Municipality","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":30,"phoneExt":30,"email":30},"Jianliu Wang",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Wang Jianliu","Vice-president of Peking University People's Hospital",[55,57,59,61,63,65,67],{"name":56,"class":6},"Peking Union Medical College Hospital",{"name":58,"class":6},"Peking University Third Hospital",{"name":60,"class":6},"Huazhong University of Science and Technology",{"name":62,"class":6},"Tianjin Medical University",{"name":64,"class":6},"Shandong University",{"name":66,"class":6},"Shengjing Hospital",{"name":68,"class":6},"Beijing Chao Yang Hospital","100558341","pd-1-inhibitor-combined-with-progesterone-treatment-in-fst-for-patients-with-mmrd-endometrial-cancer-100558341",false,"NCT06549855","PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer","PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer","Inclusion Criteria:\n\n* Be between the ages of 18-45 years old;\n* Stage IA (FIGO 2009) ;\n* Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\\&C or hysteroscopy;\n* Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR);\n* With a strong desire for fertility preservation;\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Stage IB(FIGO 2009) and above；\n* Tumour differentiation of G3 or non-endometrioid adenocarcinoma；\n* Complicated with any other malignancy；\n* Contraindicated to conservative treatment or the use of pharmaceuticals.\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.","FEMALE","18 Years","45 Years",{"count":80,"type":81},10,"ESTIMATED","INTERVENTIONAL",[84],"NA","The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.",[87,88,89],"Endometrial Cancer","Endometrioid Carcinoma","Mismatch Repair Deficiency",[91,88,92],"Fertility preservation","PD-1 inhibitor","NOT_YET_RECRUITING","2024-08-08",{"date":96,"type":97},"2024-08-12","ACTUAL",{"date":99,"type":81},"2024-10",{"date":101,"type":81},"2029-10",{"name":5,"class":6},1]